Serial FDG-PET/CT for early outcome prediction in patients with metastatic colorectal cancer undergoing chemotherapy Patients and methods: FDG-PET/CT scans were carried out at baseline and on day 14 in 41 patients with unresectable mCRC treated with a biweekly regimen of chemotherapy. Metabolic nonresponse was defined by <15% decrease in FDG uptake in the dominant proportion of the patient's lesions or if a lesion was found metabolically progressive. The PET-based response was correlated with radiological response ( primary end point) and patient's outcome (secondary end points).
Results: RECIST response rate in metabolically responding patients was 43% (10 of 23) compared with 0% (0 of 17) in nonresponding patients (P = 0.002). The metabolic assessment's predictive performance for RECIST response was sensitivity 100% [95% confidence interval (CI) 69% to 100%], specificity 57% (95% CI 37% to 75%), positive predictive value 43% (95% CI 23% to 66%), and negative predictive value 100% (95% CI 80% to 100%). Comparing metabolically responding versus nonresponding patients, the hazard ratio (HR) was 0.28 (95% CI 0.10-0.76) for overall survival and 0.57 (95% CI 0.27-1.21) for progression-free survival.
introduction
Nowadays, metastatic colorectal cancer (mCRC) patients can expect to survive >20 months, thanks to novel cytotoxics, biologicals, and more widespread resection of metastases [1, 2] .
Objective response assessment, key to evaluating benefit of treatment in solid tumors, relies on size criteria using morphological imaging [computerized tomography (CT), magnetic resonance imaging] [3, 4] and requires a wait of 6-8 weeks while on therapy. This exposes patients to the risk of developing a full range of toxic effects in case of treatment failure.
With tumor shrinkage the final step in a complex cascade of chemotherapy-induced alterations, changes in the metabolism of cellular energy should predict treatment response earlier than the tumor size changes. Positron emission tomography (PET), coupled with a CT module and 2-[fluorine-18]fluoro-2-deoxy-D-glucose (FDG) as a surrogate marker of tumor glycolytic activity, reliably assesses tumor response to treatment after one or two treatment cycles in various tumor types [5] [6] [7] [8] by linking early FDG changes to treatment outcome (time to progression/overall survival (OS)].
We conducted a prospective trial in which FDG-PET/CT scans were carried out at baseline (BL) and day 14 (D14) after one cycle of chemotherapy, with the aim of assessing the predictive value of early FDG-PET changes on objective tumor response and treatment outcome. We hypothesized that a significant reduction in tumor growth or proliferation induced by a drug without any prior effect on FDG uptake is highly improbable. We therefore anticipated a high negative predictive value (NPV) in case of stable or increasing FDG uptake during chemotherapy.
patients and methods patients
Eligible patients scheduled to receive chemotherapy for mCRC were prospectively enrolled into the study before the first treatment administration. They were required to bear at least one metabolically measurable lesion at BL FDG-PET/CT, defined as a lesion >15 mm in diameter, with a marked accumulation of FDG [maximum standard uptake value (SUVmax) > 2.5] [5] . Other enrollment criteria were performance status of less than two; measurable disease by CT according to RECIST; age > 18; ability to undergo chemotherapy, CT, and FDG-PET/CT; life expectancy of >8 weeks; and signed informed consent. There were no treatment-line restrictions, and physicians could choose from among registered mCRC treatments. Changes in therapy other than dose adaptation for toxicity were not allowed until radiological response assessment at 6-8 weeks. Follow-up examinations could be realized sooner if patients exhibited clinical signs of excessive toxicity or progression. Treatment stopping rules were defined according to either excessive toxicity or clinical or RECIST progressive disease.
All patients were treated at the Institut Jules Bordet (Brussels, Belgium). The study was registered in ClinicalTrials.gov (NCT00741481) and approved by the Institut Jules Bordet's Ethical Committee (CE1377) before initiation.
imaging methodology and response analysis
CT scanning
The BL CT scan had to be carried out <2 weeks before the first chemotherapy course. Radiological follow-up consisted of a CT scan after three courses of treatment. Target lesions were measured on 3-mm axial reconstructions. Enhanced or unenhanced CT scans were carried out according to lesion site. RECIST version 1.0 was used to classify radiological response [3] . Stable disease and partial response were confirmed on a control CT scan 6 weeks after the first assessment. RECIST analysis was carried out independently of the FDG-PET/CT analysis on target lesions not necessarily the same as those used for the metabolic analysis.
FDG-PET/CT imaging
All FDG-PET/CT imaging was carried out with a single dedicated PET/CT scanner (Discovery LS; General Electric, Milwaukee, WI). An unenhanced, low-dose, whole-body CT scan (120 keV; 60 mA) preceded PET imaging, which was started 60-75 min after the i.v. administration of 0.1 mCi (3.7 MBq) per kilogram patient body weight. The two-dimensional emission scan was acquired from skull base to mid-thigh, 4 min per bed position. CT-based attenuation correction was carried out.
BL and D14 FDG-PET/CTs were carried out under identical conditions in terms of patient preparation (≥6 h fasting) and positioning and image reconstruction and processing (ordered subset expectation maximisation; four iterations; five subsets). The time between tracer administration and start of imaging differed by a maximum of 15 min. All PET voxels were transformed from rough counts to standard uptake values (SUVs) by correcting the counts measured at the tumor for patient body weight and injected tracer activity.
FDG-PET/CT response analysis
FDG-PET/CT response was analyzed in batches by an experienced nuclear medicine physician not involved in treating the patients and blinded to both medical records and treatment outcome. The metabolic assessment process comprised three parts: identifying target lesions, appraising the metabolic response of each target lesion, and evaluating overall metabolic response.
BL and D14 PET images were reviewed using side-by-side display on a dedicated viewing and analysis station (Advantage Windows 4.2; General Electric). Target lesions were defined on the BL FDG-PET/CT scan according to intense FDG uptake (SUV > 2.5); high probability of malignancy without any signs of nontumoral origin on the CT correlate, nonconfluent with a lesion located nearby; and longest transaxial diameter >15 mm. The maximum number of target lesions per patient was 10, with a maximum of 5 lesions per metastatic site or organ.
Once the BL target lesions had been defined, a lesion-by-lesion PET response analysis was carried out. The relative change of the SUVmax measured within the lesion was calculated using the following formula:
Lesions with a delta SUVmax measurement of less than −15% were considered responding. All others were categorized as nonresponding.
Progressive lesions were those with a delta SUVmax measurement >25% according to the European Organization for Research and Treatment of Cancer (EORTC) response criteria [9] . Dominant metabolic response was used to categorize patient-based metabolic response. Dominance was defined according to the number of lesions ( primary criterion) and, in case of even numbers, according to the tumor load (secondary criterion) of responding versus nonresponding lesions. Patients were grouped into four classes: class I (all target lesions showed significant response); class II (mixed response, dominant response); class III (mixed response, dominant nonresponse); and class IV (no lesion showed response, presence of at least one progressive lesion, or apparition of a new lesion). For data analysis, classes I and II were considered as metabolic response and classes III and IV as metabolic nonresponse.
Metabolic response categorization was independently reviewed by two nuclear medicine specialists blinded to patient name and medical history. Both reviews were compared. In all cases of diagnostic discrepancy, a final unanimous consensus was achieved.
statistical analysis
Our primary hypothesis was that radiological response rates differ between patients according to whether their lesions show an early metabolic response. The trial aimed to test the null hypothesis that RECIST response rates are the same in these two groups versus the two-sided alternative that they are different, with a power of 0.90 and an alpha of 0.05. We wished to detect an increase in the metabolic responses from 10% to 50% in RECIST nonresponders versus responders, assuming a historical [10] estimation of a 50/50 distribution between the two. The sample size required was 45 patients.
The agreement in the review of metabolic response assessment between the two nuclear medicine specialists was estimated with Cohen's kappa.
Response rates were compared using the Fisher's exact test. Confidence intervals (CIs) at 95% were based on the Clopper-Pearson method.
Secondary objectives were progression-free survival (PFS) and OS. PFS was defined as the time between early response FDG-PET/CT scan and radiological documentation of progression or date of death. Patients alive without progression by the time of analysis were censored at the time of last follow-up visit. The cut-off was May 2010. OS was defined as the time between early response FDG-PET/CT scan and date of death. Kaplan-Meier estimates were used to characterize PFS and OS, and comparisons were made by using a two-sided log-rank test. Multivariate analysis was based on a Cox regression model with stepwise selection of variables. Variables with a P < 0.15 by univariate analysis were considered in the multivariate model. Table 1 . Twenty-nine (72.5%) patients received chemotherapy as first-line therapy and 11 (27.5%) as second line.
metabolic and radiological response
Discrepancies in metabolic response assessment between the two independent PET reviewers were found in 4 of 41 cases (10%; kappa value 0.82). Of the 40 eligible patients, 58% (23 of 40) showed metabolic response 2 weeks after the first treatment cycle. The radiological response in metabolically responding patients was 43% (10 of 23) compared with 0% (0 of 17) in metabolically nonresponding ones (P = 0.002). The metabolic assessment performance to predict radiological response was sensitivity 100% (95% CI 69% to 100%), specificity 57% (95% CI 37% to 75%), positive predictive value (PPV) 43% (95% CI 23% to 66%), and NPV 100% (95% CI 80% to 100%) ( Table 2) .
For the 23 metabolically responding patients, the rates of radiological response in classes I and II were similar: 45% (5 of 11) versus 42% (5 of 12) (P = 1; Table 3 ).
For the 17 metabolically nonresponding patients, the rate of radiological progression in class IV was twice as high as in class III: 70% (7 of 10) compared with 29% (2 of 7), although this difference was not statistically significant (P = 0.15). There was considerable heterogeneity in metabolic response as a consistent evolution of all target lesions was found only in 13 of 40 patients (33%; 10 patients with all lesions categorized as responding and 3 with lesions that were metabolically progressive or unresponsive). All remaining patients (68% of the study population) had mixed metabolic responses.
metabolic response and PFS-OS
Patients were followed up for up to 28 months. Information about progression is missing for only one patient, who died of complications after surgery to remove downstaged liver metastases that were initially unresectable. Median PFS was 7 months (95% CI 3-10), and the median OS was 20 months (95% CI 10-28).
A statistically significant association between early metabolic response and OS was observed: median OS was 27 months (95% CI 10-28) in metabolically responding patients and 11 months (95% CI 4-20) in metabolically nonresponding patients [P = 0.008, hazard ratio (HR) 0.28 (95% CI 0.10-0.76)] (Figure 1) .
A trend could be observed for an association between early metabolic response and PFS that did not reach statistical significance: median PFS was 8 months (95% CI 5-12) in metabolic responding patients compared with 3 months (95% CI 1-15) in metabolic nonresponding ones (P = 0.14); the HR was 0.57 (95% CI 0.27-1.21) (supplemental Figure S1 , available at Annals of Oncology online).
Patients with exclusively metabolic nonresponding lesions or at least one progressive lesion seemed to have the worst survival outcomes: comparing these 10 patients with the remaining 30, the HR was 4.78 (95% CI 1.72-13.26) for OS (P value 0.001) and 2.30 (95% CI 1.00-5.30) for PFS (P value 0.043). Among age, sex, treatment line, BL carcinoembryonic antigen level, BL performance status, number of metastatic sites, and early metabolic assessment considered as possible predictors for OS, early metabolic assessment (P = 0.003) and performance status (P < 0.001) were retained in a multivariate model (Table 4) .
discussion
This study shows that FDG uptake changes seen in patients with mCRC after a single course of chemotherapy (i) can be used to predict inability of the treatment to induce a morphological response; (ii) show significant intraindividual tumor heterogeneity; and (iii) carry significant prognostic information. These findings may have significant impact on future routine clinical management of patients and on clinical trial designs.
The aim of identifying patients with nonresponding metastatic disease early is to quickly stop ineffective treatments. This can avoid unnecessary toxic effects and possibly allow alternative more effective therapies. Meanwhile, avoiding premature termination of a potentially beneficial treatment requires a test with the highest sensitivity and NPV possible. For instance, the MUNICON trial [11] was designed to stop neoadjuvant chemotherapy for locally advanced esophageal tumors with an SUV decrease of <35% at FDG-PET assessment after 2 weeks. Using a <45% threshold would have increased the specificity of the test at the expense of a decrease in its NPV as indicated by a significant proportion (18%) of the PET nonresponding patients still showing a histopathological response at surgery. Deciding to pursue this philosophy in order to avoid metabolic imagingbased denial of potentially beneficial therapy, we applied the lowest possible reliable response threshold for FDG uptake changes (delta SUVmax of less than −15%), partly based upon the widely used EORTC criteria for FDG-PET response [9] and substantiated by a parallel study on part of our dataset by Necib et al. [12] . In the latter work, an Receiver Operating Characteristic analysis of the lesion-by-lesion FDG uptake change (SUVmax) confirmed the 15% cut-off value for FDG uptake necessary to identify RECIST-based nonresponding lesions with a >95% sensitivity and >95% NPV.
Using this threshold, we showed that early metabolic reassessment has a 100% NPV and only 43% PPV for standard RECIST-based responses and is more efficient in differentiating between patients who will not develop a radiological structural response and those who will. This observation confirms our working hypothesis that significant tumor shrinkage during treatment with drug combinations having a cytotoxic backbone is highly unlikely without an early metabolic decrease. Cytostatic treatments with lower tumor-shrinking potential should be studied in an appropriately designed study. The high NPV could have been induced by the low prevalence of response observed in our patient cohort, which received a mix of first-and second-line treatments; however, NPV remains 100% (95% CI 72-100) in first-line patients only.
The poor to moderate specificity and PPV for RECIST response might be explained as follows: (i) the metabolic response may be transient, with rapid development of resistance to treatment; (ii) a metabolic response may not always translate into subsequent significant tumor shrinkage, e. g. in case of disease stabilization; (iii) the reproducibility of SUVmax measurements may vary, as shown in studies that carried out double-BL FDG-PET scans within 5-10 days and found a relative absolute percentage difference of up to 13%, with a standard deviation of 10% [13] . Based on these data, use of a cut-off of a 15% decrease in FDG uptake during treatment could result in a number of false positives in terms of response, thereby reducing specificity. One of our study's main observations is the high prevalence (68%) of mixed metabolic responses, in which both responsive and nonresponsive PET lesions coexist within the same patient, and even sometimes within the same organ. This could be the result of significant intrapatient heterogeneity of gene expression profiles and/or microenvironmental conditions between lesions or may even reveal the coexistence of different disease patterns. Metabolic response heterogeneity has also been reported for other solid tumors such as breast cancer [14] .
No guidelines exist to translate the lesion-based mixed metabolic responses observed into a patient-based classification (response versus nonresponse).
Some authors [5, 15] have taken into consideration only the response of the lesion with the highest uptake, the mean of the change of all lesions, or the least responding lesion, thereby ignoring intertumoral heterogeneity, and particularly the progression of some lesions, which could be a relevant prognostic factor. We propose a set of patient-based PET response categories based on the dominant metabolic response considering all metabolically active lesions. This method seems acceptable from an oncological viewpoint because of its whole tumor load assessment and its high reproducibility (kappa 0.82).
Early metabolic assessment seems to correlate to overall prognosis: responding patients showed significant survival benefit over nonresponders [HR 0.38 (95% CI 0.15-0.94)]. Most importantly, in a multivariate analysis, the survival benefit of early PET response, together with BL performance status, constituted the only two parameters retained. The HR for early metabolic response hardly changed after adding treatment line (first versus second) as a confounding variable: 0.19 (95% CI 0.06-0.58), compared with 0.19 (95% CI 0.07-0.58) ( Table 4) if not corrected for line, suggesting nonsignificant impact on study outcome.
Our study does not confirm the 'flare phenomenon' reported by Findlay et al. [16] as an early increase in FDG uptake after one treatment course, followed by a marked objective response later. We identified six lesions with such an early >25% increase (ranging from 38% to 312%) in FDG uptake (three hepatic, one pleural, one peritoneal, and one retroperitoneal lesion): three of these showed stable disease and two progressive disease at a first RECIST analysis; one PET progressive bone marrow lesion was not measurable on CT.
Our data suggest that metabolism-based imaging could clarify the current 'black box' of radiologically stable diseases. These represent a mix of (i) chemorefractory tumors so slowly evolutive that current RECIST after 2 months are unable to show structural progression and (ii) partial response in previously progressive diseases, stabilized by the treatment without a significant reduction in tumor volume. The higher sensitivity of detecting antitumor effects using FDG-PET could significantly change the way active drug regimens are identified in the clinic or in drug development trials.
Our results cannot be applied to other tumor types, treatment modalities, or response time points, as confirmed by the negative findings after two courses of chemotherapy recently reported by Byström et al. [15] . The timing and cutoff value for optimal identification of nonresponding patients must be defined for each clinical setting in a preliminary study and further validated in multicentric prospective studies, using standardized and harmonized FDG-PET/CT operating procedures rigorously controlled by a central imaging lab.
conclusions
Early FDG-PET/CT metabolic reassessment after one chemotherapy cycle in patients with nonresectable mCRC is able to discriminate, with a high NPV, tumors unlikely to respond to treatment. Heterogeneity in early tumor metabolic response is present in the majority of patients and seems to have a major impact on outcome. These results, if independently validated, could have significant future impact on treatment strategies and the design of clinical trials involving solid tumors.
